Seed oils are best for LDL cholesterol

If you want to lower your low-density lipoprotein cholesterol, called LDL or, colloquially, "bad cholesterol," the research is clear about one thing: You should exchange saturated fats with unsaturated fat. If you want to know what you should use to sauté your dinner, that's a harder question to answer. Many of the studies establishing that mono- and polyunsaturated fats are better for blood lipids than saturated fats swapped out one food source at a time, making it hard to tell which of a plethora of vegetable oils might be most beneficial.

Lukas Schwingshackl, a researcher at the German Institute of Human Nutrition, is among a wave of scientists using sophisticated statistical tools to reduce uncertainty about what the mountain of data in the nutrition literature can tell us. In a paper published in the Journal of Lipid Research this month, Schwingshackl and colleagues used an emerging technique called network meta-analysis to extract insight from published studies on the effect of various dietary oils on blood lipids. The researchers found that seed oils were the best choice for people looking to improve their cholesterol.

To get around the fact that there has been no giant study comparing all available oils, Schwingshackl's team constructed a network meta-analysis showing how different oils and solid fats have in fact been matched up. The researchers rounded up 55 studies dating to the 1980s that assessed the effects of consuming the same amount of calories from two or more different oils on participants' blood lipids. To be included in the analysis, a study had to compare the effect of two or more oils or fats (from a list of 13) on patients' LDL, or other blood lipids like total cholesterol, HDL-cholesterol or triglycerides, over at least three weeks.

Suppose both butter and sunflower oil had been tested against olive oil. The statistical approaches of network meta-analysis allowed the team to infer a quantitative comparison between butter and sunflower oil, even if they had never faced off in the clinic. Schwingshackl explained, "The beauty of this method is that you can compare a lot of different interventions simultaneously... and, in the end, you get a ranking. You can say, 'this is the best oil for this specific outcome.'"

In this study, the final ranking indicated that, as your doctor has been telling you for years, solid fats like butter and lard are the worst choice for LDL. The best alternatives are oils from seeds. "Sunflower oil, rapeseed oil, safflower oil and flaxseed oil performed best," said Schwingshackl. "Some people from Mediterranean countries probably are not so happy with this result, because they would prefer to see olive oil at the top. But this is not the case."

There are a few important caveats to the research. For starters, it measured only blood lipids. "This is not a hard clinical outcome," said Schwingshackl. "LDL is a causal risk factor for coronary heart disease, but it's not coronary heart disease." However, he said, it might be difficult to conduct a study comparing those clinical outcomes -- for starters, someone would need to find study participants willing to eat just one type of fat for years at a time.

Meta-analyses run the risk of misleading by combining several pieces of low-confidence data into a falsely confident-sounding ranking. In this case, for example, there was not enough evidence to choose a "winner" confidently among the seed oils. What's more, the oils best at lowering LDL were not the most beneficial for triglycerides and HDL cholesterol. However, with the appropriate caveats in mind, Schwingshackl is optimistic about the potential for network meta-analysis to help researchers synthesize disparate clinical studies in the future.

Schwingshackl L, Bogensberger B, Benčič A, Knüppel S, Boeing H, Hoffmann G.
Effects of oils and solid fats on blood lipids: a systematic review and network meta-analysis.
J Lipid Res. 2018 Sep;59(9):1771-1782. doi: 10.1194/jlr.P085522.

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...